Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for prevention of isoniazid-induced hepatotoxicity in latent tuberculosis
IRCT20200328046886N4Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of acetylcysteine and isoniazid in Tuberculosis (TB) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Incidence of isoniazid-induced hepatotoxicity, Treatment compliance and 2 more. Started Sep 2021; status: completed.
02
Drugs
acetylcysteineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on IRCT20200328046886N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200328046886N4.